"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Descriptor ID |
D018796
|
MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
1997 | 3 | 0 | 3 |
1999 | 1 | 0 | 1 |
2000 | 2 | 0 | 2 |
2001 | 1 | 0 | 1 |
2002 | 3 | 0 | 3 |
2003 | 6 | 1 | 7 |
2004 | 2 | 1 | 3 |
2006 | 1 | 1 | 2 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 1 | 2 | 3 |
2010 | 2 | 1 | 3 |
2011 | 1 | 1 | 2 |
2012 | 6 | 0 | 6 |
2013 | 2 | 0 | 2 |
2014 | 13 | 1 | 14 |
2015 | 5 | 2 | 7 |
2016 | 5 | 4 | 9 |
2017 | 9 | 4 | 13 |
2018 | 9 | 4 | 13 |
2019 | 4 | 3 | 7 |
2020 | 9 | 2 | 11 |
2021 | 14 | 2 | 16 |
2022 | 18 | 1 | 19 |
2023 | 20 | 0 | 20 |
2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024 Apr 01; 34(4):469-477.
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Apr; 125:102720.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Antibody-Conjugated Polymersomes with Encapsulated Indocyanine Green J-Aggregates and High Near-Infrared Absorption for Molecular Photoacoustic Cancer Imaging. ACS Appl Mater Interfaces. 2024 Feb 07; 16(5):5598-5612.
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 01; 42(1):47-58.
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
-
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):e21-e32.e4.
-
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study. Mol Cancer Ther. 2023 10 02; 22(10):1191-1203.
-
Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors. Annu Rev Med. 2024 Jan 29; 75:31-48.